1228883-06-4

Basic information

• Product Name: 6,7‐dimethoxy‐3‐(4-methoxyphenyl)quinazolin‐4(3H)‐one
• Synonyms: 6,7‐dimethoxy‐3‐(4-methoxyphenyl)quinazolin‐4(3H)‐one
• CAS NO: 1228883-06-4
• Molecular Weight: 312.325
• Mol File: 1228883-06-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6,7‐dimethoxy‐3‐(4-methoxyphenyl)quinazolin‐4(3H)‐one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7‐dimethoxy‐3‐(4-methoxyphenyl)quinazolin‐4(3H)‐one(1228883-06-4)
• EPA Substance Registry System: 6,7‐dimethoxy‐3‐(4-methoxyphenyl)quinazolin‐4(3H)‐one(1228883-06-4)

Safety Data

• Hazardous Substances Data: 1228883-06-4(Hazardous Substances Data)

Upstream product

• 104-94-9 4-methoxy-aniline 
• 122-51-0 orthoformic acid triethyl ester 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 5720-07-0 4-methoxyphenylboronic acid 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 

Relevant articles and documents

Aryl Quinazolinone Derivatives as Novel Therapeutic Agents against Brain-Eating Amoebae

Naegleria fowleri and Balamuthia mandrillaris are protist pathogens that infect the central nervous system, causing primary amoebic meningoencephalitis and granulomatous amoebic encephalitis with mortality rates of over 95%. Quinazolinones and their derivatives possess a wide spectrum of biological properties, but their antiamoebic effects against brain-eating amoebae have never been tested before. In this study, we synthesized a variety of 34 novel arylquinazolinones derivatives (Q1-Q34) by altering both quinazolinone core and aryl substituents. To study the antiamoebic activity of these synthetic arylquinazolinones, amoebicidal and amoebistatic assays were performed against N. fowleri and B. mandrillaris. Moreover, amoebae-mediated host cells cytotopathogenicity and cytotoxicity assays were performed against human keratinocytes cells in vitro. The results revealed that selected arylquinazolinones derivatives decreased the viability of B. mandrillaris and N. fowleri significantly (P 0.05) and reduced cytopathogenicity of both parasites. Furthermore, these compounds were also found to be least cytotoxic against HaCat cells. Considering that nanoparticle-based materials possess potent in vitro activity against brain-eating amoebae, we conjugated quinazolinones derivatives with silver nanoparticles and showed that activities of the drugs were enhanced successfully after conjugation. The current study suggests that quinazolinones alone as well as conjugated with silver nanoparticles may serve as potent therapeutics against brain-eating amoebae.

Discovery of novel 3-benzylquinazolin-4(3H)-ones as potent vasodilative agents

In the present study, a series of 3-benzylquinazolin-4(3H)-ones were synthesized and characterized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with 60 mM KCl. The SAR of target compounds was discussed preliminarily. Among these compounds, 2a and 2c displayed potent vasodilatation action and could compete significantly the rat mesenteric arterial rings induced contraction with phenylephrine. Compounds 2a and 2c were further tested for their antihypertensive effects in SHR by oral administration. The results indicated that 2a and 2c could reduce significantly both diastolic and systolic blood pressure. Moreover, 2c displayed antihypertensive effect in a dose dependent manner, and could maintain the effects for 6 h at a dosage of 4.0 mg/kg. These findings suggest that the title compounds are novel vasodilative agents, representing a novel series of promising antihypertensive agents.